CA2335012A1 - Compositions pharmaceutiques de prevention et de traitement de troubles du systeme nerveux central - Google Patents

Compositions pharmaceutiques de prevention et de traitement de troubles du systeme nerveux central Download PDF

Info

Publication number
CA2335012A1
CA2335012A1 CA002335012A CA2335012A CA2335012A1 CA 2335012 A1 CA2335012 A1 CA 2335012A1 CA 002335012 A CA002335012 A CA 002335012A CA 2335012 A CA2335012 A CA 2335012A CA 2335012 A1 CA2335012 A1 CA 2335012A1
Authority
CA
Canada
Prior art keywords
prevention
treatment
pharmaceutical compositions
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002335012A
Other languages
English (en)
Other versions
CA2335012C (fr
Inventor
Merouane Bencherif
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catalyst Biosciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2335012A1 publication Critical patent/CA2335012A1/fr
Application granted granted Critical
Publication of CA2335012C publication Critical patent/CA2335012C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002335012A 1998-08-07 1999-06-02 Compositions pharmaceutiques de prevention et de traitement de troubles du systeme nerveux central Expired - Fee Related CA2335012C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/130,498 US6218383B1 (en) 1998-08-07 1998-08-07 Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US09/130,498 1998-08-07
PCT/US1999/012243 WO2000007600A1 (fr) 1998-08-07 1999-06-02 Compositions pharmaceutiques de prevention et de traitement de troubles du systeme nerveux central

Publications (2)

Publication Number Publication Date
CA2335012A1 true CA2335012A1 (fr) 2000-02-17
CA2335012C CA2335012C (fr) 2009-08-11

Family

ID=22444976

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002335012A Expired - Fee Related CA2335012C (fr) 1998-08-07 1999-06-02 Compositions pharmaceutiques de prevention et de traitement de troubles du systeme nerveux central

Country Status (16)

Country Link
US (1) US6218383B1 (fr)
EP (2) EP1102588B1 (fr)
JP (2) JP4750945B2 (fr)
KR (1) KR100705434B1 (fr)
AT (1) ATE418986T1 (fr)
AU (1) AU761087B2 (fr)
BR (1) BR9912805A (fr)
CA (1) CA2335012C (fr)
CY (2) CY1110309T1 (fr)
DE (1) DE69940199D1 (fr)
DK (2) DK2018874T3 (fr)
ES (2) ES2322725T3 (fr)
HK (1) HK1127290A1 (fr)
MX (1) MXPA01001435A (fr)
PT (2) PT1102588E (fr)
WO (1) WO2000007600A1 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979695B2 (en) * 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US20020052497A1 (en) * 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
US7790757B2 (en) * 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
US20050131034A1 (en) * 1998-06-16 2005-06-16 Caldwell William S. Compounds capable of activating cholinergic receptors
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
CA2376061A1 (fr) * 1999-06-07 2000-12-14 Targacept, Inc. Compositions pharmaceutiques et methodes d'utilisation
US20010036949A1 (en) * 2000-05-09 2001-11-01 Coe Jotham Wadsworth Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
CN100371714C (zh) * 2001-12-14 2008-02-27 塔加西普特公司 治疗中枢神经系统病症的方法和组合物
US7091357B2 (en) 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
US6852741B2 (en) * 2001-12-31 2005-02-08 University Of Florida Compositions and methods for treatment of neurological disorders
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
DE10212564B4 (de) * 2002-03-12 2007-04-19 Neurobiotec Gmbh 1-Allyl-ergotalkaloid-Derivate und ihre Verwendung zur Prophylaxe und Therapie von Migräne
US20070197583A1 (en) * 2002-03-29 2007-08-23 Welsh Michael J Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
US20030186860A1 (en) * 2002-03-29 2003-10-02 Welsh Michael J. Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
BRPI0418712B8 (pt) * 2004-04-02 2021-06-22 Arterial Remodelling Tech Inc método para preparar uma montagem para fornecimento de um stent polimérico degradável e bioreabsorvível, montagem para fornecer um stent degradável e bioreabsorvível e método para preparar um stent polimérico degradável e bioreabsorvível
UA88792C2 (ru) 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
EP2357174A1 (fr) 2006-05-09 2011-08-17 AstraZeneca AB Sels de (2S)-(4E)-N-méthyl-5-[(5-isopropoxy)pyridin-3-yl]-4-pentèn-2-amine
EP2089383B1 (fr) 2006-11-09 2015-09-16 Probiodrug AG Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
WO2008091592A1 (fr) * 2007-01-22 2008-07-31 Targacept, Inc. Administration intranasale, buccale et sublinguale d'analogues de métanicotine
CA2679446C (fr) 2007-03-01 2016-05-17 Probiodrug Ag Nouvelle utilisation d'inhibiteurs de la glutaminyl cyclase
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP4110198B2 (ja) * 2007-07-27 2008-07-02 株式会社東芝 半導体発光装置
WO2009017455A1 (fr) * 2007-07-30 2009-02-05 Astrazeneca Ab Nouvelle combinaison (a) d'agoniste alpha-4-bêta-2-neuronal nicotinique et (b) d'inhibiteur de gsk3
CN102026995B (zh) 2007-12-07 2014-10-29 Abbvie德国有限责任两合公司 5，6-二取代的羟吲哚衍生物和其用途
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
JP5595926B2 (ja) 2007-12-07 2014-09-24 アボット ゲーエムベーハー ウント カンパニー カーゲー ５−ハロゲン−置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
MX2010006202A (es) 2007-12-07 2011-03-04 Abbott Gmbh & Co Kg Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
US20090291150A1 (en) * 2008-05-21 2009-11-26 University Of Iowa Research Foundation Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
US9801865B2 (en) * 2008-09-24 2017-10-31 The United States Of America As Represented By The Department Of Veteran Affairs Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation
WO2010138600A2 (fr) 2009-05-29 2010-12-02 Abbott Laboratories Compositions pharmaceutiques utilisées dans le traitement de la douleur
EP2533645B1 (fr) 2010-02-09 2016-07-27 The Johns Hopkins University Procédés et compositions pour améliorer la fonction cognitive
WO2011107530A2 (fr) 2010-03-03 2011-09-09 Probiodrug Ag Nouveaux inhibiteurs
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
EP2560953B1 (fr) 2010-04-21 2016-01-06 Probiodrug AG Inhibiteurs de glutaminyl cyclase
SG185497A1 (en) 2010-05-20 2012-12-28 Astrazeneca Ab New process for the preparation of aryl substituted olefinic amines
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2968220B1 (fr) 2013-03-15 2021-05-05 Agenebio, Inc. Procédés et compositions pour améliorer la fonction cognitive
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
WO2018150276A2 (fr) 2017-02-16 2018-08-23 Universidad San Sebastian Combinaison de cotinine et d'antioxydant de traitement de dépression résistante et correction du déficit fonctionnel des astrocytes induit par la dépression et d'autres états neuropathologiques
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US560423A (en) 1896-05-19 peirce
US4965074A (en) * 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DK569087A (da) 1986-10-31 1988-05-01 Sumitomo Pharma Quinolin-derivater, deres fremstilling og anvendelse
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
FI91401C (fi) 1987-03-17 1994-06-27 Hoechst Roussel Pharma Menetelmä terapeuttisesti aktiivisten substituoitujen 9-aminotetrahydroakriinien ja niille läheisten yhdisteiden valmistamiseksi
IT1225462B (it) 1987-04-03 1990-11-14 Mediolanum Farmaceutici Srl Sali organici di derivati della fisostigmina
US5002955A (en) 1987-04-23 1991-03-26 Hoechst-Roussel Pharmaceuticals Inc. Fused heteroalkylene quinolinamines and use as cholinergic agents
ATE411026T1 (de) 1987-05-04 2008-10-15 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
US5187165A (en) 1987-05-15 1993-02-16 Hoechst-Roussel Pharmaceuticals Inc. Memory enhancing and analgesic 1,2,3a,8,8a-hexahydro-3a,8(and 1,3a,8)-di(and tri)methylpyrrolo[2,3-b]indoles
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5693668A (en) 1989-06-22 1997-12-02 Merrell Pharmaceuticals Inc. Acetylcholinesterase inhibitors
EP0403713A1 (fr) 1989-06-22 1990-12-27 Merrell Dow Pharmaceuticals Inc. Inhibiteurs d'acétylcholinestérase
US4999430A (en) 1989-07-31 1991-03-12 Warner-Lambert Company Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine
DE3927049A1 (de) 1989-08-16 1991-02-21 Sandoz Ag Halogenalkyl-phenyl-ketone und deren hydrate, ihre herstellung und verwendung
US4914102A (en) 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
NZ237241A (en) 1990-03-02 1993-11-25 Pharmetrix Corp Method for increasing the storage stability of physostigmine
US5102891A (en) 1990-07-23 1992-04-07 Hoechst-Roussel Pharmaceuticals Inc. 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates
US5264442A (en) 1990-08-13 1993-11-23 Hoechst-Roussel Pharmaceuticals Incorporated Carbamoyl-1-(pyridinylalkyl)-1H-indoles, indolines and related analogs
TW200462B (fr) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
KR0175638B1 (ko) 1991-03-01 1999-02-18 카렌 에이.홀브루크 신경계 퇴행성 질환 치료용 니코틴 아날로그의 개량된 제조방법
FR2677019B1 (fr) 1991-05-27 1994-11-25 Pf Medicament Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
PT100525B (pt) 1991-05-29 1999-10-29 Abbott Lab Azaspiranos substituidos imunomodulares, seu uso e composicoes farmaceuticas que os contem
FR2679555B1 (fr) 1991-07-25 1993-11-19 Fabre Medicament Pierre Nouveaux derives de l'uree, leur preparation et leur application en therapeutique.
US5246947A (en) 1991-09-23 1993-09-21 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
US5231093A (en) 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
TW263504B (fr) 1991-10-03 1995-11-21 Pfizer
US5413098A (en) 1991-12-24 1995-05-09 Sextant Medical Corporation Path constrained spectrophotometer and method for determination of spatial distribution of light or other radiation scattering and absorbing substances in a radiation scattering medium
ES2042384B1 (es) 1991-12-26 1994-06-01 Boehringer Ingelheim Espana Procedimiento para obtener derivados bis-piridinicos.
WO1993013083A1 (fr) 1991-12-31 1993-07-08 Fujisawa Pharmaceutical Co., Ltd. Derives d'oxadiazole a effet inhibiteur de l'acetylcholinesterase et agoniste muscarinique
JPH07505145A (ja) 1992-02-25 1995-06-08 ワーナー−ランバート・コンパニー 細胞保護組成物およびその製法および使用法
US5212188A (en) 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
US5242935A (en) 1992-03-06 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5276043A (en) 1992-04-10 1994-01-04 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5227391A (en) 1992-04-10 1993-07-13 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
IT1254996B (it) 1992-06-25 1995-10-11 Mediolanum Farmaceutici Srl Esteri amminoalchilcarbammici dell'eserolina atti all'impiego come anticolinesterasici e relativo procedimento di preparazione
US5242916A (en) * 1992-07-07 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5466696A (en) 1992-09-10 1995-11-14 Warner Lambert Company Tacrine and cytochrome P450 oxidase inhibitors and methods of use
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
IT1264765B1 (it) * 1993-03-10 1996-10-04 Rotta Research Lab Derivati dell'acido glutammico ed acido aspartico, procedimento per la loro preparazione e loro uso come farmaci potenzianti la
EP0627400A1 (fr) 1993-06-04 1994-12-07 Merrell Dow Pharmaceuticals Inc. Inhibiteurs aromatiques d'acétylcholinesterase
SE9302080D0 (sv) 1993-06-16 1993-06-16 Ab Astra New compounds
JPH09500645A (ja) * 1993-07-22 1997-01-21 ワーナー−ランバート・コンパニー 制御放出タクリン薬物送達システムおよびその製造方法
US5434170A (en) 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
US5744476A (en) 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5616707A (en) 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
JP2668670B2 (ja) * 1995-03-24 1997-10-27 日本たばこ産業株式会社 ジアザビシクロ［３．３．１］ノナン誘導体、その中間体及びその医薬用途
WO1996030372A1 (fr) 1995-03-24 1996-10-03 Japan Tobacco Inc. Derives diazabicyclo[3.3.1]nonane et leurs intermediaires, leur application therapeutique et procedes de production
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
ATE240942T1 (de) 1995-11-17 2003-06-15 Merck & Co Inc Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
DK0892796T3 (da) 1996-04-12 2001-11-19 Aventis Pharma Inc Isatinderivater som acetylcholinesteraseinhibitorer og analgetika
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
CA2180703A1 (fr) 1996-07-08 1998-01-09 Paul Marie Victor Gilis Comprime de bromhydrate de galanthamine a dissolution rapide
CA2289574C (fr) * 1997-05-30 2007-04-24 Neurosearch A/S Derives de 8-azabicyclo[3.2.1]oct-2-ene et -octane utilises comme ligands cholinergiques de recepteurs nicotiniques de l'ach
US7727473B2 (en) 2005-10-19 2010-06-01 Progentech Limited Cassette for sample preparation
JP5597919B2 (ja) * 2008-11-05 2014-10-01 株式会社三洋物産 制御基板の収納構造

Also Published As

Publication number Publication date
PT1102588E (pt) 2009-02-26
CY1110309T1 (el) 2015-01-14
EP1102588A1 (fr) 2001-05-30
JP4750945B2 (ja) 2011-08-17
EP2018874B1 (fr) 2014-08-13
MXPA01001435A (es) 2003-09-10
ES2322725T3 (es) 2009-06-25
JP2002522390A (ja) 2002-07-23
KR100705434B1 (ko) 2007-04-09
CA2335012C (fr) 2009-08-11
ATE418986T1 (de) 2009-01-15
CY1115589T1 (el) 2017-01-04
AU761087B2 (en) 2003-05-29
AU4328599A (en) 2000-02-28
DE69940199D1 (de) 2009-02-12
EP1102588B1 (fr) 2008-12-31
JP2011137027A (ja) 2011-07-14
BR9912805A (pt) 2001-05-02
KR20010072631A (ko) 2001-07-31
DK1102588T3 (da) 2009-04-14
EP2018874A3 (fr) 2012-11-21
WO2000007600A1 (fr) 2000-02-17
PT2018874E (pt) 2014-10-16
HK1127290A1 (en) 2009-09-25
DK2018874T3 (da) 2014-10-13
EP2018874A2 (fr) 2009-01-28
US6218383B1 (en) 2001-04-17
ES2515120T3 (es) 2014-10-29

Similar Documents

Publication Publication Date Title
CA2335012A1 (fr) Compositions pharmaceutiques de prevention et de traitement de troubles du systeme nerveux central
AU3495397A (en) Muscarinic antagonists
EP0807633A3 (fr) (5,6)-Pyrimidin-4-ones condensées à hétéroaryle, substituées en 2,3
CA2333703A1 (fr) Derives isothiazole utiles en tant qu'agents anticancereux
IL127244A (en) Substituted amines, methods of their preparation and pharmaceutical compositions containing them
CA2244785A1 (fr) Pentafluorobenzenesulfonamides et analogues
IL114599A (en) Substituted pyrimidine compounds their preparation and pharmaceutical compositions containg them
WO1999020606A3 (fr) Nouvelles piperidines et piperazines utiles en tant qu'inhibiteurs de l'agregation plaquettaire
CA2094702A1 (fr) Derives de substitution de tetrahydropyridines et d'hydroxypiperidines, agents therapeutiques pour le systeme nerveux central
WO2000023057A3 (fr) Therapie visant a ameliorer la cognition
CA2094703A1 (fr) Derives de la piperazine, agents therapeutiques pour le systeme nerveux central
NZ509762A (en) 5-Azatricyclo[3.3.1.1<3,7>]decane derivatives, pharmaceuticals thereof, and their use as cholinergic receptor agonists and antagonists
CA2237189A1 (fr) 3-azetidinylalkylpiperidines ou -pyrrolidines en tant qu'antagonistes des tachykinines
EP1032556A4 (fr) Composes pharmaceutiquement actifs et procedes d'utilisation
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
CA2282279A1 (fr) Atropisomeres de 3-heteroaryl-4(3h)-quinazolinones pour le traitement des troubles neurodegeneratifs et des troubles lies a un traumatisme du systeme nerveux central
CA2192822A1 (fr) Utilisation d'agents immunosuppresseurs dans le traitement de la schizophrenie
WO2000033788A3 (fr) Composes heterocycliques azotes substitues et leur utilisation therapeutique
WO2000021512A3 (fr) Composition et procede pour le traitement d'allergies
EP0804186A4 (fr) Composes alkaloides du type indole-diterpene
WO2003026564A3 (fr) Composition pharmaceutique
CA2332535A1 (fr) Medicament anti-angiogenique pour le traitement du cancer, de l'arthrite et de la retinopathie
WO2001004090A3 (fr) Tetrahydro-isoquinolines et tetrahydrothienopyridines neurotrophiques, compositions et procedes associes
AU7589298A (en) 5-{(heteroaryl)alkyl}-3-oxo-pyrido{1,2-(a)}benzimidazole-4-c arboxamide derivatives useful in treating central nervous system disorders
EP0928792A3 (fr) Hexanes (3.1.0) bicycliques et composés apparentés

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160602